Loading company
Loading
Open Financials Omega Therapeutics, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2023 | FY2022 | Change | Source |
|---|---|---|---|---|
| Revenue | $3.1 million | $2.1 million | +49.3% | 10-K 2024-03-28 · proof |
| Operating income | -$100.3 million | -$102.8 million | 10-K 2024-03-28 · proof | |
| Net income | -$97.4 million | -$102.7 million | 10-K 2024-03-28 · proof | |
| Cash from operating activities | -$91.5 million | -$98.5 million | 10-K 2024-03-28 · proof | |
| Free cash flow | -$94.4 million | -$99.9 million | 10-K 2024-03-28 · proof | |
| Total assets | $204.4 million | $146 million | +40% | 10-K 2024-03-28 · proof |
| Total liabilities | $146.4 million | $40 million | +265.6% | 10-K 2024-03-28 · proof |
| Cash and cash equivalents | $68.4 million | $70.6 million | -3.1% | 10-K 2024-03-28 · proof |
| Total debt | $18.9 million | $19.9 million | -5.3% | 10-Q 2024-05-06 · proof |
- What was Omega Therapeutics, Inc.'s revenue in fiscal 2023?
- Omega Therapeutics, Inc. reported revenue of $3.1 million for fiscal 2023 (the year ended Dec 31, 2023), against $2.1 million the year before (+49.3%). Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What was Omega Therapeutics, Inc.'s operating income in fiscal 2023?
- Omega Therapeutics, Inc. reported operating income of -$100.3 million for fiscal 2023 (the year ended Dec 31, 2023), against -$102.8 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What was Omega Therapeutics, Inc.'s net income in fiscal 2023?
- Omega Therapeutics, Inc. reported net income of -$97.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$102.7 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What was Omega Therapeutics, Inc.'s cash from operating activities in fiscal 2023?
- Omega Therapeutics, Inc. reported cash from operating activities of -$91.5 million for fiscal 2023 (the year ended Dec 31, 2023), against -$98.5 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What was Omega Therapeutics, Inc.'s free cash flow in fiscal 2023?
- Omega Therapeutics, Inc. reported free cash flow of -$94.4 million for fiscal 2023 (the year ended Dec 31, 2023), against -$99.9 million the year before. Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What are Omega Therapeutics, Inc.'s total assets?
- As of Dec 31, 2023, Omega Therapeutics, Inc. reported total assets of $204.4 million, against $146 million a year earlier (+40%). Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What are Omega Therapeutics, Inc.'s total liabilities?
- As of Dec 31, 2023, Omega Therapeutics, Inc. reported total liabilities of $146.4 million, against $40 million a year earlier (+265.6%). Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What are Omega Therapeutics, Inc.'s cash and cash equivalents?
- As of Dec 31, 2023, Omega Therapeutics, Inc. reported cash and cash equivalents of $68.4 million, against $70.6 million a year earlier (-3.1%). Source: the 10-K filed with the SEC on Mar 28, 2024. SEC
- What is Omega Therapeutics, Inc.'s total debt?
- As of Dec 31, 2023, Omega Therapeutics, Inc. reported total debt of $18.9 million, against $19.9 million a year earlier (-5.3%). Source: the 10-Q filed with the SEC on May 6, 2024 (restated). SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1850838&period_type=annual&limit=5"Information only, not investment advice.